Taipale C, et al. - Researchers conducted this prospective randomized clinical trial to optimize the aflibercept treat-and-extend protocol in wet age-related macular degeneration (wAMD). The sample consisted of 52 eyes from 52 patients with treatment-naïve wAMD. Three monthly aflibercept injections were obtained by patients and then randomized 1:1 to two different dosing protocols. The 1-year follow-up was finished by 50 patients. Between the study groups, patient and ophthalmic baseline variables were similar. According to findings, the anatomical and functional responses were comparable in one year between the protocols of moderate and rapid extensions, with fewer aflibercept injections in the rapid extension protocol. Data reported that 48% of eyes reached a 12-week treatment interval or beyond at 1 year in the rapid extensions protocol.